FOXO unit Vector BioSource agrees to buy four Grifols blood collection centers for $3.5 million plus up to $1 million earnout
FOXO•Vector BioSource to acquire four Grifols blood collection centers
FOXO Technologies unit Vector BioSource agreed to buy assets tied to four Grifols blood collection centers in the US.
- Deal value: $3.5 million cash at closing; earn-out up to $1 million tied to EBITDA through 2028.
- Closing targeted for Q3 or Q4 2026; either party can terminate if it has not closed within nine months.
- Completion requires a new FDA license, CLIA certification, and a Miami waste-management permit separate from Grifols.
